The UT Southwestern Medical Center in Dallas is one of the select academic institutions in America today where treatment and research of malignant pleural mesothelioma cancer is a priority.
The mesothelioma program at UT Southwestern is part of a broader Lung Disease and Respiratory Disorders umbrella that offers patients some of the most advanced diagnostic and interventional treatments available anywhere.
The multidisciplinary clinical program includes cardiothoracic surgeons, medical and radiation oncologists, pulmonologists and nurses, all versed in mesothelioma treatment and working together to provide the best possible care.
Lung specialists are trained in the personalized approach to cancer care, taking advantage of both a top-notch clinical staff and an innovative research program to form a partnership with each patient.
“We’re at the center of quite a number of things, both across the country and around the world,” said thoracic surgeon Dr. Kemp Kernstine, a mesothelioma and lung specialist. “This really is an amazing place.”
There are 13 different, but closely linked cancer care programs at its Simmons Cancer Center, the region’s only National Cancer Institute-designated program.
The programs include:
The lung cancer team at Simmons has considerable experience in caring for mesothelioma patients, whose numbers at the hospital have increased in recent years, stemming from Kernstine’s arrival in 2010.
Kernstine, professor and chair of the division of thoracic surgery, is one of the leaders of the lung cancer team. He has handled pleural mesothelioma patients for many years, performing both the extrapleural pneumonectomy (EPP) and the pleurectomy/decortication (P/D), the most aggressive surgeries possible for the disease.
Hematology oncology associate professor Dr. Jonathan Dowell works closely with thoracic malignancy patients, including those with mesothelioma. He also is an active clinical researcher, particularly with non-small and small cell lung cancers and mesothelioma.
Oncologist Dr. David Gerber, who is co-director of the Experimental Therapeutics of Cancer research group, does much of the adjuvant and neoadjuvant therapy with mesothelioma patients.
Pulmonologist Dr. Muhanned Abu-Hijleh, has worked with lung cancer, pleural diseases and other thoracic malignancies like mesothelioma for many years.
Dr. Hak Choy is the chair of the radiation oncology department at UT Southwestern. He is lauded for developing new drugs that combine well with the latest technology in radiation. He has an expertise in stereotactic body radiation therapy and image-guided radiation therapy (IGRT).
As part of its vast research work, UT Southwestern Medical Center has an Experimental Therapeutics of Cancer department that studies how genetic variations among individuals affects responses to treatment and tumor growth in different cancers.
Scientists there study the molecular makeup of cancers and how those differences influence the behavior of tumors, helping to personalize the therapies that are prescribed at UT Southwestern.
Also, there are research departments dedicated to chemistry and cancer, cancer cell networks, lung cancer and cancer control. These are designed to ease the overall burden of this disease.
There are close to 200 clinical trials in various stages underway at the Simmons Cancer Center, including a prominent one for malignant pleural mesothelioma treatment.
Simmons is part of a multicenter, phase II trial testing the effectiveness of defactinib (VS-6063), a drug designed for the targeted killing of mesothelioma cancer stem cells. It also is being tested with ovarian and non-small-cell lung cancer.
It is a randomized, placebo-controlled study designed for patients who already have had at least four cycles of chemotherapy with at least a partial response.
Stem cells represent only a small percentage of cells in a tumor and are the underlying cause of cancer metastasis and tumor recurrence. Defactinib is designed to obstruct the particular protein in the stem cells that help them grow.
UT Southwestern has been promoting its early screening programs for lung and colon cancer, making sure its discoveries in the laboratory are used in the community.
The cancer prevention and detection program has been particularly successful among the medically underserved.
There also is an impressive cancer genetics program that closely monitors known families with higher hereditary risk of colon and uterine cancers, along with gene mutations linked to ovarian and breast cancers.
The UT Southwestern Medical Center is world-renowned for its research, well-respected for its high quality clinical care and is highly regarded for its ability to teach and train those for the future. Many of its research advances have helped the local community, but also the cancer community through the country and beyond.
Disclaimer: University of Texas Southwestern Medical Center has no professional affiliation with Asbestos.com.
Tim Povtak is an award-winning writer with more than 30 years of reporting national and international news. His specialty is interviewing top mesothelioma specialists and researchers, reporting the latest news at mesothelioma cancer centers and talking with survivors and caregivers. Read More